Establishment of Heterochromatin
异染色质的建立
基本信息
- 批准号:8258797
- 负责人:
- 金额:$ 31.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-05-01 至 2015-04-30
- 项目状态:已结题
- 来源:
- 关键词:AffectAllelesCellsCentromereChromatinChromosomesComplexDNA SequenceDefectDependenceDevelopmentDicer EnzymeDiseaseEukaryotaEventFission YeastFunctional RNAFutureGene MutationGene SilencingGenerationsGenesGeneticGenomeGenomic ImprintingGoalsHealthHereditary DiseaseHeterochromatinHistone H3Homologous GeneHot SpotHumanKnowledgeLeadLysineMacromolecular ComplexesMaintenanceMalignant NeoplasmsMammalsMediatingMethylationMethyltransferaseModelingMolecularMutationOrganismOther GeneticsPathway interactionsPlayProcessProtein BindingProteinsPublishingRNARNA InterferenceRecruitment ActivityRelianceResearchResolutionRoleShapesSiteSmall Interfering RNAStructureSystemTestingWorkX InactivationYeastsbasecell growthcell typechromatin immunoprecipitationchromosome lossflyhistone methyltransferaseinterestmutantnovelpreventresearch studytherapy developmenttumorigenesis
项目摘要
DESCRIPTION (provided by applicant): Normal cellular differentiation and development rely extensively on silencing mechanisms. Disruption of silencing can lead to genetic disorders, chromosome loss and contribute to tumorigenesis. Our long term goal is to determine the normal mechanisms that lead to establishment and maintenance of silenced regions (heterochromatin) of the genome. The goal of this proposal is to define how heterochromatin at centromeres is established. A major impediment to research on the establishment of heterochromatin has been difficulty in separating establishment from maintenance. To circumvent this problem, we utilize the exquisite genetic tractability of the fission yeast, where silenced chromatin shares many features with mammals, including reliance on similar chromatin marking systems and a shared dependence on non-coding RNA and the RNAi pathway for silencing control. Through characterization of a macromolecular complex that is important for the assembly of heterochromatin, we generated a novel mutant strain of yeast that can maintain pre-assembled heterochromatin, but cannot support its de-novo establishment. We will use this mutant to screen genes that are known to play a role in heterochromatin stability to identify those that are required for heterochromatin establishment. We have already found that one "establishment" gene that encodes a histone methyltransferase, Clr4, (the homolog of Suv39 proteins in flies and mammals) which methylates histone H3 on lysine 9 (K9) only in regions of heterochromatin. We anticipate that other "establishment" genes will regulate Clr4's recruitment to chromatin and / or its activity. Second, we will determine the DNA sequences that are required for the establishment of heterochromatin. We will define "hot-spots" for Clr4 activity using high resolution chromatin immunoprecipitation analyses, and will assess whether these sequences suffice to establish de novo heterochromatin. We will determine which establishment genes work through which establishment sequences. Finally, we will determine if K9 methylation of histone H3 suffices to establish heterochromatin, and the role that the proteins that bind this mark play in the establishment of heterochromatin. These studies will yield a basic knowledge of the mechanisms that dictate heterochromatin establishment and will provide a framework for future work directed towards understanding and developing therapies for aberrant heterochromatin assembly and disease-related silencing defects in humans. PUBLIC HEALTH RELEVANCE: The "turning-off" or silencing of specific regions of chromosomes is as important for the normal growth of cells in an organism as is "turning-on" genes. Silencing is important for cell-type identity and for enabling all cells to divide normally, such that improper silencing can contribute to genetic disorders and cancer. The proposed studies are directly relevant as they will yield a basic knowledge of silencing and help direct future work towards understanding and developing therapies for disease- related silencing defects in humans.
描述(由申请人提供):正常的细胞分化和发育广泛依赖于沉默机制。沉默的破坏会导致遗传疾病,染色体丧失并导致肿瘤发生。我们的长期目标是确定导致基因组沉默区域(异染色质)建立和维持的正常机制。该提案的目的是定义如何建立Centromeres的异染色质。对建立异染色质的研究的主要障碍很难将建立与维护分开。为了解决这个问题,我们利用了裂变酵母的精致遗传障碍性,在该酵母中,沉默的染色质与哺乳动物具有许多特征,包括依赖类似的染色质标记系统以及对非编码RNA的共同依赖性以及对沉默控制的RNAI途径。 通过对异染色质组装很重要的大分子复合物的表征,我们产生了一种新型的酵母突变菌株,可以维持预组装的异染色质,但不能支持其De-Novo的建立。我们将使用该突变体来筛选已知在异染色质稳定性中发挥作用的基因,以鉴定异染色质建立所需的基因。我们已经发现,一个编码组蛋白甲基转移酶CLR4(果蝇中SUV39蛋白的同源物和哺乳动物的同源物)的一个“建立”基因,该基因仅在异染色质区域中甲基于赖氨酸9(K9)上的组蛋白H3甲基化。我们预计其他“机构”基因将调节CLR4招募到染色质和 /或其活性。其次,我们将确定建立异染色质所需的DNA序列。我们将使用高分辨率的染色质免疫沉淀分析来定义CLR4活性的“热点”,并将评估这些序列是否足以建立从头杂染色质。我们将确定哪些建立基因可以通过哪种建立序列起作用。最后,我们将确定组蛋白H3的K9甲基化是否足以建立异染色质,以及结合该标记在异染色质建立中发挥的蛋白质的作用。这些研究将对决定异染色质建立的机制产生基本知识,并将为未来的工作提供一个框架,用于理解和开发异常异染色质组装和疾病相关的沉默缺陷的疗法。公共卫生相关性:染色体特定区域的“关闭”或沉默对于生物体中细胞的正常生长和“转动”基因一样重要。沉默对于细胞类型的身份和使所有细胞正常分裂至关重要,从而使沉默不当会导致遗传疾病和癌症。拟议的研究直接相关,因为它们将产生沉默的基本知识,并有助于将未来的工作朝着理解和开发与人类相关的疾病沉默缺陷的疗法。
项目成果
期刊论文数量(9)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
SHREC Silences Heterochromatin via Distinct Remodeling and Deacetylation Modules.
- DOI:10.1016/j.molcel.2016.03.016
- 发表时间:2016-04-21
- 期刊:
- 影响因子:16
- 作者:Job G;Brugger C;Xu T;Lowe BR;Pfister Y;Qu C;Shanker S;Baños Sanz JI;Partridge JF;Schalch T
- 通讯作者:Schalch T
Spreading the silence.
蔓延着沉默。
- DOI:10.1016/j.devcel.2009.05.002
- 发表时间:2009
- 期刊:
- 影响因子:11.8
- 作者:Partridge,JanetF
- 通讯作者:Partridge,JanetF
Should I stay or should I go? Chromodomain proteins seal the fate of heterochromatic transcripts in fission yeast.
我应该走还是留?
- DOI:10.1016/j.molcel.2012.07.007
- 发表时间:2012
- 期刊:
- 影响因子:16
- 作者:Creamer,KevinM;Partridge,JanetF
- 通讯作者:Partridge,JanetF
Sir2 is required for Clr4 to initiate centromeric heterochromatin assembly in fission yeast.
- DOI:10.1038/emboj.2013.143
- 发表时间:2013-08-28
- 期刊:
- 影响因子:11.4
- 作者:Alper, Benjamin J.;Job, Godwin;Yadav, Rajesh K.;Shanker, Sreenath;Lowe, Brandon R.;Partridge, Janet F.
- 通讯作者:Partridge, Janet F.
RITS-connecting transcription, RNA interference, and heterochromatin assembly in fission yeast.
- DOI:10.1002/wrna.80
- 发表时间:2011-09
- 期刊:
- 影响因子:7.3
- 作者:Creamer, Kevin M.;Partridge, Janet F.
- 通讯作者:Partridge, Janet F.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JANET F PARTRIDGE其他文献
JANET F PARTRIDGE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JANET F PARTRIDGE', 18)}}的其他基金
相似国自然基金
基于人诱导多能干细胞技术研究突变等位基因特异性敲除治疗1型和2型长QT综合征
- 批准号:82300353
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
PML等位基因突变介导急性早幼粒细胞白血病患者对三氧化二砷耐药的分子机制研究
- 批准号:
- 批准年份:2020
- 资助金额:24 万元
- 项目类别:青年科学基金项目
p38调控CARD9(S12N)杂合子等位基因表达不平衡导致ABPA发生的机制研究
- 批准号:81901673
- 批准年份:2019
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
等位基因调控TGM6表达介导巨噬细胞极化在抗结核免疫中的作用与机制研究
- 批准号:81970007
- 批准年份:2019
- 资助金额:56 万元
- 项目类别:面上项目
人类基因组中等位基因在父源和母源的基因组中的特异表达和基因印记
- 批准号:81871168
- 批准年份:2018
- 资助金额:57.0 万元
- 项目类别:面上项目
相似海外基金
Role of intestinal serotonin transporter in post traumatic stress disorder
肠道血清素转运蛋白在创伤后应激障碍中的作用
- 批准号:
10590033 - 财政年份:2024
- 资助金额:
$ 31.7万 - 项目类别:
Modulation of NOD Strain Diabetes by ENU-Induced Mutations
ENU 诱导突变对 NOD 菌株糖尿病的调节
- 批准号:
10642549 - 财政年份:2023
- 资助金额:
$ 31.7万 - 项目类别:
Characterizing Entorhinal Cortex Circuit Dysfunction in an APOE Mouse Model of Chemotherapy-Induced Cognitive Impairment
化疗引起认知障碍的 APOE 小鼠模型中内嗅皮层回路功能障碍的特征
- 批准号:
10677984 - 财政年份:2023
- 资助金额:
$ 31.7万 - 项目类别:
Effects of Aging on Neuronal Lysosomal Damage Responses Driven by CMT2B-linked Rab7
衰老对 CMT2B 相关 Rab7 驱动的神经元溶酶体损伤反应的影响
- 批准号:
10678789 - 财政年份:2023
- 资助金额:
$ 31.7万 - 项目类别:
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 31.7万 - 项目类别: